IL1RAP and triple-negative breast carcinoma: IL1RAP overexpression has been described in hematological cancers such as CML and AML, as well as in solid tumors such as pancreatic ductal adenocarcinoma, Ewing sarcoma [51], glioma, triple negative breast cancer, non-small cell lung cancer, stomach adenocarcinoma, or cervical cancer [50].